BrachyDOSE is a pioneering Lithuanian medtech startup specializing in radiotherapy dose measurement tools. Founded in 2014, its headquarters is based in Kaunas, Lithuania. The company was founded by Neringa Šeperienė, an expert in materials engineering, and Rimas Šeperys. BrachyDOSE aims to enhance the precision and safety of cancer treatments through the development of innovative hardware and software systems that integrate seamlessly with existing radiotherapy workflows. The company recently raised €554,000 in a funding round led by Coinvest Capital, highlighting its progress and potential within the healthcare industry.
| Attribute | Information |
|---|---|
| Founding Date | 2014 |
| Headquarters | Kaunas, Lithuania |
| Founders | Neringa Šeperienė, Rimas Šeperys |
| Revenue | Not disclosed |
| Profits | Not disclosed |
| Key Investors | Coinvest Capital, BSV Ventures, LitBAN, EstBAN |
| Industry | MedTech, HealthTech |
| Number of Employees | 3 |
BrachyDOSE began its journey in Kaunas, Lithuania, during 2014 with the vision of enhancing cancer treatment through precise radiation measurement. The company's founders, bringing expertise from materials engineering and healthcare startups, aimed to fill gaps in treatment accuracy and safety. Initial development focused on integrating advanced sensors and algorithms to predict radiation exposure effects, ultimately enhancing decision-making in therapy settings. This focus on high-tech solutions rapidly set BrachyDOSE apart in Lithuania's burgeoning healthtech sector.
BrachyDOSE’s business model revolves around providing innovative solutions for radiotherapy departments worldwide. Utilizing a combination of hardware sensors and imbedded software, the company offers:
BrachyDOSE operates at the intersection of medical technology and oncology, primarily targeting cancer treatment centers across Europe and the US. Their technology is currently undergoing clinical trials, supported by substantial funding aimed at obtaining necessary EU certifications. Known for its ability to potentially halve preparation times for procedures and reduce treatment-related costs significantly, BrachyDOSE stands ahead in competitive healthtech by ensuring market readiness and scalability. Their ongoing involvement with international cancer programs indicates strategic positioning towards global market integration.
BrachyDOSE represents a significant advancement in radiation measurement technology, potentially redefining the standards for cancer treatment safety and efficiency. By focusing on innovation and strategic growth, the company holds an influential position within the medtech industry. As it progresses toward commercialization, BrachyDOSE's impact on enhancing treatment accuracy aligns with the broader objectives of improving health outcomes and operational efficiencies in oncology care. Its future trajectory seems poised for successful expansion beyond the Baltic region into major European and US markets.